Role of brachytherapy in patients with stage T(1c), T(2a) adenocarcinoma of the prostate

Journal of Endourology

Volumn 14, Issue 4, 2000, Pages 319-324

  Chan, Andrew J ^a   Saltzman, Brian ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; HISTORY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY;

EID: 0033935674     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2000.14.319     Document Type: Article

References (26)

1. Gerber GS, Chodak GW. Routine screening for cancer of the prostate. J Natl Cancer Inst 1991;83:329-335.
2. Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Database Report on Prostate Cancer following the peak in incidence rates in the United States. Cancer (in press).
3. Scardino PT, Carlton CE. Combined interstitial and external irradiation for prostatic cancers. In: Principles and Management of Urologic Cancer. Baltimore: Williams & Wilkins, 1983, pp 392-408.
4. Whitmore WF, Hilaris B, Grabstald H. Retropubic implantation of iodine-125 in the treatment of prostatic carcinoma. J Urol 1972;108:918.
5. Russell KJ, Blasko JC. Recent advances in interstitial brachytherapy for localized prostate cancer. Probl Urol 1993;7:260.
6. Koprowski CD, Berkenstock KG, Borofski AM, et al. External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinoma. Int J Radiat Oncol Biol Phys 1991;21:955-960.
7. Kuban DA, Anas EM, Schelhammer PF. I-125 interstitial implantation for prostate cancer: What have we learned 10 years later? Cancer 1989;63:2415-2420.
8. Morton JD, Peschel RE. Iodine-125 implants versus external beam therapy for stages A2, B, and C prostate cancer. Int J Radiat Oncol Biol Phys 1988;14:1153-1157.
9. Giles GM, Brad LW. 125-Iodine implantation after lymphadenectomy in early carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1986;12:2117.
10. Fuks Z, Leibel SA, Wallner KE, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125-I implantation. Int J Radiat Oncol Biol Phys 1991;21:537.
11. Blasko JC, Ragde H, Luse RW, et al. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 1996;23:633-650.
12. Holm HH, Juul N, Pederson JF, et al. Transperineal iodine-125 seed implantation in prostate cancer guided by transrectal ultrasonography. J Urol 1983;130:283-286.
13. Wallner K, Chiu-Tsao ST, Roy J, et al. An improved method for computerized tomography planned transperineal 125-iodine prostate implants. J Urol 1991;146:90-95.
14. Pollack A, Zagars GK, Davadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 1994;74:670.
15. Wallner K, Jitendra R, Harrison L. Tumor control and morbidity following transperineal iodine-125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-453.
16. Grado GL, Larson TR, Balch CS, et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998;42:289-298.
17. Ragde H, Blasko JC, Grimm PD, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442-453.
18. Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998;83:989-1001.
19. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
20. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999;17:517-522.
21. Blasko JC, Grimm PD, Ragde H. Transperineal ultrasound guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol 1991;Suppl 137:113-118.
22. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998;160:1379-1382.
23. Wallner K, Lee H, Wasserman S, et al. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997;37:565-569.
24. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994;152:1831-1836
25. Grimm PD, Blasko JC, Ragde H, et al. Does brachytherapy have a role in the treatment of prostate cancer? Hematol Oncol Clin North Am 1996;10:653-673.
26. Blasko JC, Grimm PD, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993;3:240-249.